1.Effectiveness of Brassica juncea (mustard green) leaf decoction as an adjunct in the treatment of type 2 diabetes mellitus among Filipinos: a randomized clinical trial.
Samantha Pauline G. CHIO ; Ma. Elaine D. CHUA ; Monica B. CORALDE ; Raphael Carlos P. COVAR ; Mariah Sandrine M. DATING ; Janica Crissel Y. FRANCISCO ; Kryzta Kate V. GABAY ; Bianca Marguerite DG. GATBONTON ; Jose Jonathan F. GIRON ; Herald Jervy D. GO ; Clarissa Isabel B. HERNANDEZ ; Tsung Jen HOU ; Monaflor Abigail G. IGNACIA ; Anna Victoria F. ILAGAN ; Remigio Jay-Ar Z. BUTACAN
Health Sciences Journal 2018;7(2):81-85
Introduction This study aimed to determine the effectiveness of mustard green leaf decoction as an adjunct to drug treatment in controlling blood glucose among Filipinos with type 2 diabetes mellitus.
Methods Participants were randomly assigned to receive mustard decoction or a placebo solution for eight weeks on top of their oral anti-hyperglycemic medication. Fasting blood sugar and complete blood counts were determined at baseline, Week 4 and Week 8, and compared within and across the two groups.
Results There was a decreasing trend in the blood sugar in the mustard green group while the opposite was noted in the placebo group. The mean FBS levels of the mustard green group were significantly lower than that of the placebo group at the Week 8 determination (6.10 vs 8.69 mmol/L, p=0.0004). The decrease in blood sugar level on the eight week in the mustard green group was significant compared with the baseline level (p=0.008).
Conclusion This study had demonstrated that the intake of Brassica juncea decoction can significantly decrease blood sugar level among type 2 diabetics compared to metformin alone.
Male ; Female ; Middle Aged (a Person 45-64 Years Of Age) ; Adult (a Person 19-44 Years Of Age)
2.Effectiveness of Brassica juncea (mustard green) leaf decoction as an adjunct in the treatment of type 2 diabetes mellitus among Filipinos: a randomized clinical trial.
Samantha Pauline G. Chio ; Ma. Elaine D. Chua ; Monica B. Coralde ; Raphael Carlos P. Covar ; Mariah Sandrine M. Dating ; Janica Crissel Y. Francisco ; Kryzta Kate V. Gabay ; Bianca Marguerite DG. Gatbonton ; Jose Jonathan F. Giron ; Herald Jervy D. Go ; Clarissa Isabel B. Hernandez ; Tsung-Jen Hou ; Monaflor Abigail G. Ignacio ; Anna Victoria F. Ilagan ; Remigio Jay-Ar Z. Butacan IV
Health Sciences Journal 2018;7(2):80-85
INTRODUCTION:
This study aimed to determine the effectiveness of mustard green leaf decoction as an adjunct to drug treatment in controlling blood glucose among Filipinos with type 2 diabetes mellitus.
METHODS:
Participants were randomly assigned to receive mustard green decoction or a placebo solution for eight weeks on top of their oral anti-hyperglycemic medication. Fasting blood sugar and complete blood counts were determined at baseline, Week 4 and Week 8, and compared within and across the two groups.
RESULTS:
There was a decreasing trend in the blood sugar level in the mustard green group while the opposite was noted in the placebo group. The mean FBS levels of the mustard green group were significantly lower than that of the placebo group at the Week 8 determination (6.10 vs 8.69 mmol/ L, p = 0.004). The decrease in blood sugar level on the eighth week in the mustard green group was significant compared with the baseline level (p = 0.008).
CONCLUSION
This study has demonstrated that the intake of Brassica juncea decoction can significantly decrease blood sugar levels among type 2 diabetics compared to metformin alone.
3.Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
Pin-Nan CHENG ; Wen-Jone CHEN ; Charles Jia-Yin HOU ; Chih-Lin LIN ; Ming-Ling CHANG ; Chia-Chi WANG ; Wei-Ting CHANG ; Chao-Yung WANG ; Chun-Yen LIN ; Chung-Lieh HUNG ; Cheng-Yuan PENG ; Ming-Lung YU ; Ting-Hsing CHAO ; Jee-Fu HUANG ; Yi-Hsiang HUANG ; Chi-Yi CHEN ; Chern-En CHIANG ; Han-Chieh LIN ; Yi-Heng LI ; Tsung-Hsien LIN ; Jia-Horng KAO ; Tzung-Dau WANG ; Ping-Yen LIU ; Yen-Wen WU ; Chun-Jen LIU
Clinical and Molecular Hepatology 2024;30(1):16-36
Metabolic dysfunction-associated fatty liver disease (MAFLD) is an increasingly common liver disease worldwide. MAFLD is diagnosed based on the presence of steatosis on images, histological findings, or serum marker levels as well as the presence of at least one of the three metabolic features: overweight/obesity, type 2 diabetes mellitus, and metabolic risk factors. MAFLD is not only a liver disease but also a factor contributing to or related to cardiovascular diseases (CVD), which is the major etiology responsible for morbidity and mortality in patients with MAFLD. Hence, understanding the association between MAFLD and CVD, surveillance and risk stratification of MAFLD in patients with CVD, and assessment of the current status of MAFLD management are urgent requirements for both hepatologists and cardiologists. This Taiwan position statement reviews the literature and provides suggestions regarding the epidemiology, etiology, risk factors, risk stratification, nonpharmacological interventions, and potential drug treatments of MAFLD, focusing on its association with CVD.